Sentence examples for microarray technology that from inspiring English sources

BlueGnome manufactures genetic screening kits based on microarray technology that let fertility doctors screen IVF embryos for chromosomal abnormalities such as extra copies of chromosomes, as seen in people with Down syndrome.

Despite advances in microarray technology that have led to increased reproducibility and substantial reductions in the cost of microarrays, the successful use of this technology is still elusive for many researchers, and microarray data analysis in particular presents a substantial bottleneck for many biomedical researchers.

Unlike RNA- or DNA-based microarray technology that has the capacity to identify thousands of gene differences between samples, 2D-GE/MS generates a manageable number of protein differences.

We previously developed a protein microarray technology that allows construction of the complete predicted proteome of a microorganism [6], [7], [8], [9], [10].

In the original study, the authors used a cDNA microarray technology that allowed them to measure gene expression of several thousand genes on 112 samples, including 41 normal prostate specimens, 62 primary prostate tumours and 9 lymph node metastases.

Genome tiling arrays are a recent advances in microarray technology that involve the representation of a target genome by a virtual 'tile path' consisting of oligonucleotide probes [16], [17].

Moreover, with the advent of microarray technologies that allow the RNA output of thousands of genes to be monitored in a single experiment, it becomes increasingly more difficult to interpret and integrate thousands of output values and their changes, when the system is perturbed in multiple distinct ways.

We have taken advantage of recent advances in cell purification, RNA amplification, and microarray technologies that allow the study of gene expression of purified subsets of cells on a genome-wide scale.

This was recognized by the FDA Critical Path Initiative [ 1] which calls for development of new biomarkers, asserting that new microarray technologies, that can rapidly analyze the expression of thousands of genes, may make it possible to identify sets of biomarkers that are more predictive of clinical risks or benefits than single markers for a given condition.

Though there are many studies of gene expression based on microarray technologies that suggest candidate genes for the prognosis or outcome for ALL patients [ 11– 15], to date all the validation studies have focused on a small number of genes or in strategies tailored to specific disease subgroups.

Notably not all these errors are due to pseudogene co-amplification; however, mistakes from pseudogenes may increase with improved sequencing methods and highly sensitive re-sequencing microarray technologies that have a lower detection limit than traditional sequencing and which readily detect low-level heteroplasmy [ 11, 26].